Development History of Immunodeficient Mice and Their Research Applications
By John Charpentier, Ph.D. October 25, 2022 Since the characterization of the nude mouse in 1962, genetic mouse models of immunodeficiency have been increasingly developed,…
Read more
Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy
BEIJING, China and FORT LAUDERDALE, FL., Oct. 18, 2022 (BUSINESS WIRE) – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals…
Read more
Biocytogen to Present Progress of Preclinical and Clinical Assets at BIO-EUROPE 2022
Beijing, China, October 17, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) will present at the upcoming BIO-EUROPE conference in Leipzig, Germany on…
Read more
AAPS Pharmsci 360® 2022
As a premiere provider of pharmacology services and tools that accelerate the pace of preclinical research, Biocytogen is thrilled to be an exhibitor at PharmSci 360®. Stop…
Read more
10th annual Immuno-Oncology Summit
Over the past 10 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage…
Read more
IWHM6 | Biocytogen to Present 12 Posters on Innovative Mouse and Rat Models
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) will attend the 6th International Workshop on Humanized Mice (IWHM6) held in Kyoto University, Japan, from October…
Read more
Research Impact: B-NDG Mice Used to Identify Lipid Transport Mechanism Driving T Cell Leukemogenesis
By John Charpentier, Ph.D. September 29, 2022 A recent study featuring Biocytogen mice identifies a non-vesicular lipid transport mechanism required for T cell leukemogenesis. Wenbing…
Read more
Biocytogen to Present at BioJapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress
Biocytogen will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules, will introduce: Five RenMiceTM-based fully human…
Read more
Breakfast & Biotech with Biocytogen
Biocytogen eagerly invites fellow industrial partners and colleagues to join us for a Biotech and Breakfast session at the MassBio Hub. About this event Therapeutic…
Read more
Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy
Beijing and Guangzhou, China, September 15, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co.,…
Read more